MyFinsight
Home
Blog
About
Contact
Download
Download image
Cash and cash
equivalents
$442,209K
Accounts receivable, net
$392,046K
Inventory
$129,029K
Short-term investment
securities
$72,221K
Other current assets
$51,464K
Total current assets
$1,086,969K
Deferred tax assets
$344,136K
Long-term investment
securities
$61,538K
Non-current inventories
$26,346K
Right of use assets
$6,481K
Other noncurrent
assets
$2,015K
Restricted cash
$1,352K
Total assets
$1,528,837K
Total liabilities and
stockholders equity
$1,528,837K
Total liabilities
$945,706K
Total stockholders
equity
$583,131K
Accumulated deficit
-$1,062,238K
Treasury stock, at cost,
6,871,546 and 3,543,643...
$200,226K
Loan payable
non-current
$745,140K
Total current
liabilities
$187,108K
Deferred revenue,
non-current portion
$6,863K
Lease liability
non-current
$6,595K
Additional paid-in capital
$1,845,435K
Common stock, 0.001 par
value per share...
$160K
Accounts payable and
accrued expenses
$148,845K
Accrued compensation
$18,655K
Deferred revenue -
current portion
$17,190K
Lease liability
current portion
$1,822K
Other current
liabilities
$596K
Back
Back
Balance Sheet
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
source: myfinsight.com